Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Device Investors Buoyed By Secondhand Optimism

This article was originally published in Start Up

Executive Summary

Venture capitalists still might find medical devices to be among the more difficult sectors to place their money, but the overall mood of device investors is improving. Device VCs are encouraged by increasing opportunities on Wall Street along with interest from corporate investors, but limited partners and the FDA remain primary concerns.

You may also be interested in...

VC Funding In 2013: Some Impressive Device Rounds, But Momentum Shifts To Biotech

Medtech start-ups have closed on some impressive venture capital funding rounds so far this year, with the largest investments concentrated in a few “hot” technology areas. But the biotechnology industry garnered far more VC funding in Q2 than did the medical device sector, particularly with regards to early-stage funding.

START-UP’s 2013 Life Science Venture Capital Survey: The Responses

In START-UP’s third annual life science venture capital survey, we sent respondents down various tracks depending upon their strategic focus (biopharma vs. device), their employer (traditional venture firm vs. corporate venture group), and other variations. Here are the questions and the complete survey responses.

Better Living Through Chemistry: Biopharma Investors Weigh In

In our third annual Life Science VC Survey, those who invest in biopharmaceuticals are feeling good about the IPO window and the helping hand from corporate VCs, and for the third year in a row, they say oncology and rare disease are top investment targets.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts